Study on the Efficacy of PD-1 Monoclonal Antibody Combined with Albumin-Bound Paclitaxel and Nedaplatin Chemotherapy in the Treatment of Locally Advanced Esophageal Cancer
Objective To investigate the efficacy of programmed death receptor 1(PD-1)monoclonal antibody combined with albumin-bound paclitaxel and nedaplatin chemotherapy in the treatment of locally advanced esophageal cancer.Methods Sixty patients with locally advanced esophageal cancer admitted to The 989th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from January 2021 to June 2023 were selected and divided into two groups based on different treatment regimens,with 30 cases in each group.The control group received albumin-bound paclitaxel and nedaplatin chemotherapy,while the observation group received camrelizumab combined with albumin-bound paclitaxel and nedaplatin chemotherapy.The treatment effects of the two groups were compared.Results The short-term objective response rate(80.00%)in the observation group was higher than that in the control group(50.00%),with statistically significant differences(P＜0.05).There was no statistically significant difference in the short-term disease control rate between the observation group(100.00%)and the control group(93.33%)(P＞0.05).After treatment,the levels of carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 19-9(CA19-9),and squamous cell carcinoma antigen(SCC-Ag)in the observation group were lower than those in the control group,with statistically significant differences(P＜0.05).After treatment,the T cell subsets(CD3+,CD4+,CD4+/CD8+)in the observation group were higher than those in the control group,with statistically significant differences(P＜0.05).After treatment,the levels of PD-1 and programmed death-ligand 1(PD-L1)in the observation group were lower than those in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of PD-1 monoclonal antibody,albumin-bound paclitaxel,and nedaplatin chemotherapy is effective in treating locally advanced esophageal cancer.It can reduce tumor marker levels,enhance immune function,regulate PD-1 and PD-L1 levels,and has a high safety profile.
万方数据
维普
